ACE and COVID-19: However, one recent report demonstrates that angiotensin‐converting enzyme inhibitors (ACEI) and Angiotensin II receptor blocker (ARB) may reduce the mortality risk of COVID‐19 patients, raising the question if and how hypertension drugs interfere with virus replication in COVID‐19 patients.